Clinical trials
Completed Leiomyosarcoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
78 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 5 |
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 78 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 12 |
| National Cancer Institute (NCI) | 9 |
| Memorial Sloan Kettering Cancer Center | 7 |
| Dana-Farber Cancer Institute | 3 |
| Baylor College of Medicine | 2 |
| Eli Lilly and Company | 2 |
| Institut Bergonié | 2 |
| M.D. Anderson Cancer Center | 2 |
| Massachusetts General Hospital | 2 |
| Sarcoma Alliance for Research through Collaboration | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leiomyosarcoma | 78 |
| Sarcoma | 58 |
| Liposarcoma | 49 |
| Histiocytoma, Malignant Fibrous | 38 |
| Sarcoma, Synovial | 38 |
| Fibrosarcoma | 32 |
| Hemangiosarcoma | 32 |
| Neurofibrosarcoma | 31 |
| Rhabdomyosarcoma | 20 |
| Sarcoma, Alveolar Soft Part | 15 |
Trials
Showing 1 to 25 of 78. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.